Methods and arrangements for reducing oversensing and/or providing diagnostic information in implantable medical devices

• US 7,756,570 B1
• Filed: 05/01/2006
• Issued: 07/13/2010
• Est. Priority Date: 05/01/2006
• Status: Expired due to Fees

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Inventors: Bornzin, Gene A.
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): MALAMUD, DEBORAH LESLIE
• Application Number:
  US11/414,837
• Time in Patent Office: 1,534 Days
• Field of Search: 600508-509, 600515-518, 600/521, 607/5, 607/7, 128898-899, 128/920
• US Class Current: 600/509
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/37 Monitoring; Protecting
• CPC Class Codes: A61N 1/3925 Monitoring; Protecting
• CPC Class Codes: A61N 1/3956 Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
• CPC Class Codes: Y10S 128/92 Computer assisted medical diagnostics

Abstract

An exemplary method to reduce risk of ventricular oversensing includes sensing, in vivo, amplitude of electrical cardiac activity, comparing sensed amplitude to a low sensitivity threshold where if the comparing indicates that sensed amplitude does not meet or exceed the low sensitivity threshold then further comparing the sensed amplitude to a high sensitivity threshold and if the further comparing indicates that sensed amplitude meets or exceeds the high sensitivity threshold then determining that ventricular fibrillation may exist. Various exemplary devices, systems, methods, etc., are disclosed.

Claims

1. A method comprising:

sensing, in vivo, a first waveform cycle corresponding to electrical cardiac activity, the first waveform cycle comprising a first portion and a second portion subsequent the first portion;

comparing the amplitude of the first portion of the first cycle to a low sensitivity threshold;

if the comparing indicates that the amplitude of the first portion of the first cycle does not meet or exceed the low sensitivity threshold then further comparing the amplitude of the second portion of the first cycle to a high sensitivity threshold;

if the further comparing indicates that the amplitude of the second portion of the first cycle meets or exceeds the high sensitivity threshold then determining that ventricular fibrillation may exist;

if ventricular fibrillation may exist, delivering a ventricular pacing pulse;

detecting for an evoked response; and

if an evoked response is detected, determining that ventricular fibrillation does not exist;

terminating delivery of ventricular pacing pulses;

sensing, in vivo, a subsequent waveform cycle corresponding to electrical cardiac activity, the subsequent waveform cycle comprising a first portion and a second portion subsequent the first portion;

comparing the amplitude of the first portion to the low sensitivity threshold; and

if the comparing indicates that the amplitude of the first portion meets or exceeds the low sensitivity threshold, confirming that ventricular fibrillation does not exist.

2. The method of claim 1 wherein the sensing occurs through use of one or more leads positioned in or proximate to a chamber of a heart.

3. The method of claim 1 wherein the comparing to a low sensitivity threshold, the comparing to a high sensitivity threshold and the determining rely on logic implemented by an implantable cardiac stimulation device.

4. The method of claim 1 wherein detecting for an evoked response comprises comparing the amplitude of sensed electrical cardiac activity at the time of the pacing pulse to the low sensitivity threshold.

5. The method of claim 1 further comprising, if ventricular fibrillation may exist, calling for the charging of a charge storage device for possible delivery of a defibrillation shock.

6. The method of claim 5 further comprising, if an evoked response is detected, terminating charging of the charge storage device.

7. The method of claim 1 wherein ventricular pacing pulses are delivered in accordance with a programmed atrio-ventricular (AV) delay and delivering a ventricular pacing pulse comprises shortening the AV delay prior to delivery of the pulse.

8. The method of claim 1 wherein confirming that ventricular fibrillation does not exist further comprises:

comparing the amplitude of the second portion to the high sensitivity threshold; and

if the comparing indicates that the amplitude of the second portion does not meet or exceed the high sensitivity threshold then confirming that ventricular fibrillation does not exist.

9. An implantable medical device comprising:

means for sensing, in vivo, a first waveform cycle corresponding to electrical cardiac activity, the first waveform cycle comprising a first portion and a second portion subsequent the first portion;

means for comparing the amplitude of the first portion of the first cycle to a low sensitivity threshold;

means for further comparing the amplitude of the second portion of the first cycle to a high sensitivity threshold if the comparing to the low sensitivity threshold indicates that the amplitude of the first portion of the first cycle does not meet or exceed the low sensitivity threshold then further;

means for determining that ventricular fibrillation may exist if the further comparing indicates that the amplitude of the second portion of the first cycle meets or exceeds the high sensitivity threshold;

means for delivering a ventricular pacing pulse if ventricular fibrillation may exist;

means for detecting for an evoked response; and

means for, if an evoked response is detected, determining that ventricular fibrillation does not exist;

terminating delivery of ventricular pacing pulses;

sensing, in vivo, a subsequent waveform cycle corresponding to electrical cardiac activity, the subsequent waveform cycle comprising a first portion and a second portion subsequent the first portion;

comparing the amplitude of the first portion to the low sensitivity threshold; and

if the comparing indicates that the amplitude of the first portion meets or exceeds the low sensitivity threshold, confirming that ventricular fibrillation does not exist.